Time Frame |
Up to 3 years from start of Block 1 to end of protocol therapy
|
Adverse Event Reporting Description |
Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution via expedited reporting (NCI AdEERs / CAeRs). All remaining CTCAEs collected by means other than expedited reporting are non-serious and are reported in the "AE Other" table. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
|
|
Arm/Group Title
|
Block 1 Induction Therapy
|
Arm A (HR and IR Control)
|
Arm B (HR and IR Blinatumomab)
|
Arm C (LR Control)
|
Arm D (LR Blinatumomab)
|
Blinatumomab Salvarage Therapy
|
Arm/Group Description |
All relapsed B-ALL patients enrolle...
|
Patients receive Block 2 over 4 wee...
|
Patients receive Blinatumomab Block...
|
Patients receive Block 2 over 4 wee...
|
Patients receive Block 2 over 4 wee...
|
Patients receive Blinatumomab Block...
|
Arm/Group Description |
All relapsed B-ALL patients enrolled on AALL1331 for Block 1 induction therapy.
|
Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo allogeneic HSCT if eligible. Patients with persistent testicular involvement after Block 1 receive testicular radiation during the Block 2.
|
Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT if eligible. Patients with persistent testicular involvement after Block 1 receive testicular radiation during the first block of blinatumomab.
|
Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8 weeks, Continuation 2 over 8 weeks, and then Maintenance. CNS3 patients receive chemoradiation post-Maintenance Cycle 1. Patients with persistent testicular involvement after Block 1 receive testicular radiation during Block 2.
|
Patients receive Block 2 over 4 weeks, Blinatumomab Cycle 1 over 5 weeks, Continuation 1 over 8 weeks, Blinatumomab Cycle 2 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab Cycle 3 over 5 weeks, and then Maintenance. CNS3 patients receive chemoradiation post Maintenance Cycle 1. Patients with persistent testicular involvement after Block 1 receive testicular radiation during Block 2.
|
Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT if eligible. Patients with persistent testicular involvement after Block 1 receive testicular radiation during the first block of blinatumomab.
|
|
|
Block 1 Induction Therapy
|
Arm A (HR and IR Control)
|
Arm B (HR and IR Blinatumomab)
|
Arm C (LR Control)
|
Arm D (LR Blinatumomab)
|
Blinatumomab Salvarage Therapy
|
|
Affected / at Risk (%) |
|
Affected / at Risk (%) |
|
Affected / at Risk (%) |
|
Affected / at Risk (%) |
|
Affected / at Risk (%) |
|
Affected / at Risk (%) |
|
Total |
24/661 (3.63%)
|
|
9/109 (8.26%)
|
|
5/107 (4.67%)
|
|
3/129 (2.33%)
|
|
0/127 (0.00%)
|
|
2/27 (7.41%)
|
|
|
|
Block 1 Induction Therapy
|
Arm A (HR and IR Control)
|
Arm B (HR and IR Blinatumomab)
|
Arm C (LR Control)
|
Arm D (LR Blinatumomab)
|
Blinatumomab Salvarage Therapy
|
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Total |
63/661 (9.53%)
|
|
26/109 (23.85%)
|
|
45/107 (42.06%)
|
|
16/129 (12.40%)
|
|
69/127 (54.33%)
|
|
16/27 (59.26%)
|
|
Blood and lymphatic system disorders |
|
|
|
|
|
|
Anemia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
3 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Disseminated intravascular coagulation |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Febrile neutropenia |
7/661 (1.06%)
|
8 |
5/109 (4.59%)
|
5 |
3/107 (2.80%)
|
3 |
5/129 (3.88%)
|
6 |
19/127 (14.96%)
|
27 |
6/27 (22.22%)
|
6 |
Cardiac disorders |
|
|
|
|
|
|
Atrial fibrillation |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cardiac arrest |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cardiac disorders - Other, specify |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Heart failure |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Left ventricular systolic dysfunction |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Pericardial effusion |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Sinus bradycardia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Sinus tachycardia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Supraventricular tachycardia |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Endocrine disorders |
|
|
|
|
|
|
Adrenal insufficiency |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Endocrine disorders - Other, specify |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Eye disorders |
|
|
|
|
|
|
Eye pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Optic nerve disorder |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Papilledema |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Photophobia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Retinal detachment |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Gastrointestinal disorders |
|
|
|
|
|
|
Abdominal distension |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Abdominal pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
3 |
1/27 (3.70%)
|
1 |
Anal mucositis |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Colonic perforation |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Diarrhea |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Esophageal hemorrhage |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Gastric hemorrhage |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Gastrointestinal disorders - Other, specify |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Mucositis oral |
2/661 (0.30%)
|
2 |
4/109 (3.67%)
|
4 |
1/107 (0.93%)
|
1 |
4/129 (3.10%)
|
4 |
2/127 (1.57%)
|
2 |
2/27 (7.41%)
|
2 |
Nausea |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
2 |
1/27 (3.70%)
|
1 |
Oral pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Pancreatitis |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Typhlitis |
2/661 (0.30%)
|
2 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Vomiting |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
3/127 (2.36%)
|
3 |
1/27 (3.70%)
|
1 |
General disorders |
|
|
|
|
|
|
Death NOS |
4/661 (0.61%)
|
4 |
2/109 (1.83%)
|
2 |
2/107 (1.87%)
|
2 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Edema face |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Edema limbs |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Fatigue |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Fever |
2/661 (0.30%)
|
2 |
1/109 (0.92%)
|
1 |
5/107 (4.67%)
|
5 |
1/129 (0.78%)
|
1 |
10/127 (7.87%)
|
10 |
2/27 (7.41%)
|
2 |
Flu like symptoms |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
General disorders and administration site conditions - Other, specify |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hypothermia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Infusion related reaction |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Multi-organ failure |
4/661 (0.61%)
|
4 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Non-cardiac chest pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
3/107 (2.80%)
|
3 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
2 |
1/27 (3.70%)
|
1 |
Sudden death NOS |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hepatobiliary disorders |
|
|
|
|
|
|
Cholecystitis |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hepatic failure |
3/661 (0.45%)
|
3 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Immune system disorders |
|
|
|
|
|
|
Anaphylaxis |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cytokine release syndrome |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
5/107 (4.67%)
|
5 |
0/129 (0.00%)
|
0 |
6/127 (4.72%)
|
7 |
3/27 (11.11%)
|
3 |
Immune system disorders - Other, specify |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Infections and infestations |
|
|
|
|
|
|
Anorectal infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Appendicitis |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Bronchial infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Catheter related infection |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
3/107 (2.80%)
|
3 |
0/129 (0.00%)
|
0 |
11/127 (8.66%)
|
12 |
0/27 (0.00%)
|
0 |
Conjunctivitis infective |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Encephalitis infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Enterocolitis infectious |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Eye infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Infections and infestations - Other, specify |
7/661 (1.06%)
|
8 |
3/109 (2.75%)
|
3 |
2/107 (1.87%)
|
2 |
1/129 (0.78%)
|
1 |
7/127 (5.51%)
|
8 |
1/27 (3.70%)
|
1 |
Kidney infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Lip infection |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Lung infection |
2/661 (0.30%)
|
2 |
1/109 (0.92%)
|
2 |
4/107 (3.74%)
|
5 |
2/129 (1.55%)
|
3 |
5/127 (3.94%)
|
5 |
1/27 (3.70%)
|
2 |
Meningitis |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Periorbital infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Sepsis |
26/661 (3.93%)
|
31 |
10/109 (9.17%)
|
11 |
3/107 (2.80%)
|
4 |
5/129 (3.88%)
|
5 |
4/127 (3.15%)
|
4 |
1/27 (3.70%)
|
1 |
Sinusitis |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
2/129 (1.55%)
|
2 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Skin infection |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Soft tissue infection |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Upper respiratory infection |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
3 |
1/107 (0.93%)
|
2 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
2/27 (7.41%)
|
2 |
Urinary tract infection |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
2 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Injury, poisoning and procedural complications |
|
|
|
|
|
|
Bruising |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Vascular access complication |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Investigations |
|
|
|
|
|
|
Activated partial thromboplastin time prolonged |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Alanine aminotransferase increased |
1/661 (0.15%)
|
1 |
2/109 (1.83%)
|
2 |
5/107 (4.67%)
|
5 |
2/129 (1.55%)
|
4 |
6/127 (4.72%)
|
7 |
4/27 (14.81%)
|
4 |
Alkaline phosphatase increased |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Aspartate aminotransferase increased |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
1/129 (0.78%)
|
1 |
3/127 (2.36%)
|
4 |
2/27 (7.41%)
|
2 |
Blood bilirubin increased |
3/661 (0.45%)
|
3 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
3/127 (2.36%)
|
3 |
1/27 (3.70%)
|
1 |
Cardiac troponin I increased |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Cholesterol high |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Creatinine increased |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Ejection fraction decreased |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Electrocardiogram QT corrected interval prolonged |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
GGT increased |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
3/107 (2.80%)
|
3 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Investigations - Other, specify |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Lipase increased |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
2/27 (7.41%)
|
2 |
Lymphocyte count decreased |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
5/107 (4.67%)
|
5 |
0/129 (0.00%)
|
0 |
3/127 (2.36%)
|
4 |
0/27 (0.00%)
|
0 |
Neutrophil count decreased |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
3/107 (2.80%)
|
3 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Platelet count decreased |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Serum amylase increased |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Weight gain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Weight loss |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
White blood cell decreased |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
4/107 (3.74%)
|
4 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Metabolism and nutrition disorders |
|
|
|
|
|
|
Acidosis |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Anorexia |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Dehydration |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
3/127 (2.36%)
|
3 |
0/27 (0.00%)
|
0 |
Hypercalcemia |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Hyperglycemia |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Hyperkalemia |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Hypertriglyceridemia |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Hyperuricemia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Hypoalbuminemia |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Hypocalcemia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
3/107 (2.80%)
|
3 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Hypoglycemia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Hypokalemia |
3/661 (0.45%)
|
3 |
3/109 (2.75%)
|
3 |
4/107 (3.74%)
|
5 |
2/129 (1.55%)
|
2 |
5/127 (3.94%)
|
6 |
5/27 (18.52%)
|
5 |
Hypomagnesemia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Hyponatremia |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Hypophosphatemia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
3/27 (11.11%)
|
3 |
Metabolism and nutrition disorders - Other, specify |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Tumor lysis syndrome |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
2/27 (7.41%)
|
2 |
Musculoskeletal and connective tissue disorders |
|
|
|
|
|
|
Arthralgia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Bone pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Flank pain |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Generalized muscle weakness |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Muscle weakness left-sided |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Muscle weakness right-sided |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Myalgia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Pain in extremity |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
|
|
|
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Treatment related secondary malignancy |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Nervous system disorders |
|
|
|
|
|
|
Amnesia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Aphonia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Ataxia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Cognitive disturbance |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Concentration impairment |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Depressed level of consciousness |
2/661 (0.30%)
|
2 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Dizziness |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Dysarthria |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Dysphasia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Edema cerebral |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Encephalopathy |
4/661 (0.61%)
|
4 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
0/129 (0.00%)
|
0 |
4/127 (3.15%)
|
4 |
0/27 (0.00%)
|
0 |
Facial muscle weakness |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Headache |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
3/127 (2.36%)
|
3 |
0/27 (0.00%)
|
0 |
Hydrocephalus |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Intracranial hemorrhage |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Memory impairment |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Nervous system disorders - Other, specify |
1/661 (0.15%)
|
2 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Paresthesia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Peripheral motor neuropathy |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Peripheral sensory neuropathy |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Reversible posterior leukoencephalopathy syndrome |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Seizure |
3/661 (0.45%)
|
3 |
1/109 (0.92%)
|
1 |
5/107 (4.67%)
|
5 |
0/129 (0.00%)
|
0 |
7/127 (5.51%)
|
7 |
0/27 (0.00%)
|
0 |
Stroke |
3/661 (0.45%)
|
3 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Tremor |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
0/129 (0.00%)
|
0 |
4/127 (3.15%)
|
4 |
0/27 (0.00%)
|
0 |
Pregnancy, puerperium and perinatal conditions |
|
|
|
|
|
|
Pregnancy, puerperium and perinatal conditions - Other, specify |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Psychiatric disorders |
|
|
|
|
|
|
Agitation |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Anxiety |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
2 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Confusion |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
3/107 (2.80%)
|
3 |
0/129 (0.00%)
|
0 |
4/127 (3.15%)
|
4 |
0/27 (0.00%)
|
0 |
Delirium |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Hallucinations |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Insomnia |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Personality change |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Psychiatric disorders - Other, specify |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Restlessness |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Suicidal ideation |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Renal and urinary disorders |
|
|
|
|
|
|
Acute kidney injury |
3/661 (0.45%)
|
3 |
1/109 (0.92%)
|
1 |
2/107 (1.87%)
|
2 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Renal calculi |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Renal colic |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Respiratory, thoracic and mediastinal disorders |
|
|
|
|
|
|
Adult respiratory distress syndrome |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Bronchopulmonary hemorrhage |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cough |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Dyspnea |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Epistaxis |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
2/27 (7.41%)
|
2 |
Hypoxia |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
0/129 (0.00%)
|
0 |
3/127 (2.36%)
|
3 |
1/27 (3.70%)
|
1 |
Pleural effusion |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Pneumothorax |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Pulmonary edema |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Pulmonary hypertension |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Respiratory failure |
12/661 (1.82%)
|
12 |
3/109 (2.75%)
|
3 |
2/107 (1.87%)
|
2 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Respiratory, thoracic and mediastinal disorders - Other, specify |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Sleep apnea |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Skin and subcutaneous tissue disorders |
|
|
|
|
|
|
Bullous dermatitis |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Erythroderma |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Rash maculo-papular |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Social circumstances |
|
|
|
|
|
|
Social circumstances - Other, specify |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Vascular disorders |
|
|
|
|
|
|
Capillary leak syndrome |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Hematoma |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Hypertension |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Hypotension |
9/661 (1.36%)
|
9 |
2/109 (1.83%)
|
2 |
3/107 (2.80%)
|
3 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Thromboembolic event |
3/661 (0.45%)
|
3 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Term from vocabulary, CTCv4
Indicates events were collected by systematic assessment
|
|
Frequency Threshold for Reporting Other Adverse Events
|
0%
|
|
Block 1 Induction Therapy
|
Arm A (HR and IR Control)
|
Arm B (HR and IR Blinatumomab)
|
Arm C (LR Control)
|
Arm D (LR Blinatumomab)
|
Blinatumomab Salvarage Therapy
|
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Total |
456/661 (68.99%)
|
|
92/109 (84.40%)
|
|
103/107 (96.26%)
|
|
118/129 (91.47%)
|
|
123/127 (96.85%)
|
|
26/27 (96.30%)
|
|
Blood and lymphatic system disorders |
|
|
|
|
|
|
Anemia |
5/661 (0.76%)
|
5 |
70/109 (64.22%)
|
134 |
82/107 (76.64%)
|
124 |
86/129 (66.67%)
|
207 |
95/127 (74.80%)
|
236 |
20/27 (74.07%)
|
33 |
Blood and lymphatic system disorders - Other, specify |
1/661 (0.15%)
|
1 |
2/109 (1.83%)
|
3 |
1/107 (0.93%)
|
1 |
4/129 (3.10%)
|
6 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
4 |
Disseminated intravascular coagulation |
2/661 (0.30%)
|
2 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Febrile neutropenia |
191/661 (28.90%)
|
204 |
55/109 (50.46%)
|
71 |
2/107 (1.87%)
|
2 |
78/129 (60.47%)
|
165 |
63/127 (49.61%)
|
126 |
7/27 (25.93%)
|
7 |
Lymph node pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Spleen disorder |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Thrombotic thrombocytopenic purpura |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cardiac disorders |
|
|
|
|
|
|
Aortic valve disease |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cardiac arrest |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cardiac disorders - Other, specify |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
5 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
2 |
3/127 (2.36%)
|
3 |
1/27 (3.70%)
|
1 |
Chest pain - cardiac |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Conduction disorder |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Left ventricular systolic dysfunction |
3/661 (0.45%)
|
3 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Palpitations |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Pericardial effusion |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
2 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Sinus bradycardia |
2/661 (0.30%)
|
2 |
4/109 (3.67%)
|
6 |
5/107 (4.67%)
|
6 |
4/129 (3.10%)
|
4 |
6/127 (4.72%)
|
6 |
2/27 (7.41%)
|
3 |
Sinus tachycardia |
10/661 (1.51%)
|
10 |
22/109 (20.18%)
|
25 |
28/107 (26.17%)
|
37 |
35/129 (27.13%)
|
45 |
32/127 (25.20%)
|
53 |
9/27 (33.33%)
|
9 |
Supraventricular tachycardia |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Tricuspid valve disease |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Ventricular arrhythmia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Ventricular tachycardia |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Ear and labyrinth disorders |
|
|
|
|
|
|
Ear pain |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
3 |
3/129 (2.33%)
|
3 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Hearing impaired |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Middle ear inflammation |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Tinnitus |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Vestibular disorder |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Endocrine disorders |
|
|
|
|
|
|
Adrenal insufficiency |
1/661 (0.15%)
|
1 |
4/109 (3.67%)
|
5 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Cushingoid |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
2/127 (1.57%)
|
3 |
0/27 (0.00%)
|
0 |
Hyperthyroidism |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hypothyroidism |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
3 |
0/27 (0.00%)
|
0 |
Eye disorders |
|
|
|
|
|
|
Blurred vision |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
1/107 (0.93%)
|
1 |
10/129 (7.75%)
|
11 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Cataract |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Conjunctivitis |
0/661 (0.00%)
|
0 |
8/109 (7.34%)
|
8 |
4/107 (3.74%)
|
5 |
19/129 (14.73%)
|
20 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Corneal ulcer |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Dry eye |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
3 |
1/107 (0.93%)
|
1 |
4/129 (3.10%)
|
4 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Eye disorders - Other, specify |
1/661 (0.15%)
|
1 |
2/109 (1.83%)
|
3 |
3/107 (2.80%)
|
4 |
7/129 (5.43%)
|
7 |
3/127 (2.36%)
|
3 |
0/27 (0.00%)
|
0 |
Eye pain |
1/661 (0.15%)
|
1 |
5/109 (4.59%)
|
6 |
4/107 (3.74%)
|
5 |
17/129 (13.18%)
|
17 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Floaters |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Glaucoma |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Keratitis |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
4/129 (3.10%)
|
4 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Optic nerve disorder |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Photophobia |
0/661 (0.00%)
|
0 |
4/109 (3.67%)
|
4 |
4/107 (3.74%)
|
4 |
9/129 (6.98%)
|
9 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Uveitis |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Watering eyes |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Gastrointestinal disorders |
|
|
|
|
|
|
Abdominal distension |
3/661 (0.45%)
|
3 |
6/109 (5.50%)
|
7 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Abdominal pain |
18/661 (2.72%)
|
18 |
19/109 (17.43%)
|
23 |
19/107 (17.76%)
|
23 |
30/129 (23.26%)
|
35 |
26/127 (20.47%)
|
32 |
5/27 (18.52%)
|
6 |
Anal hemorrhage |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Anal mucositis |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
3 |
0/107 (0.00%)
|
0 |
3/129 (2.33%)
|
4 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Anal pain |
1/661 (0.15%)
|
1 |
3/109 (2.75%)
|
3 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Ascites |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
2 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cheilitis |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Colitis |
4/661 (0.61%)
|
4 |
3/109 (2.75%)
|
3 |
0/107 (0.00%)
|
0 |
5/129 (3.88%)
|
5 |
3/127 (2.36%)
|
4 |
0/27 (0.00%)
|
0 |
Constipation |
2/661 (0.30%)
|
2 |
20/109 (18.35%)
|
22 |
24/107 (22.43%)
|
30 |
23/129 (17.83%)
|
28 |
19/127 (14.96%)
|
31 |
3/27 (11.11%)
|
3 |
Dental caries |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
3 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Diarrhea |
14/661 (2.12%)
|
15 |
20/109 (18.35%)
|
27 |
14/107 (13.08%)
|
17 |
36/129 (27.91%)
|
39 |
23/127 (18.11%)
|
26 |
5/27 (18.52%)
|
5 |
Dry mouth |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Dyspepsia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Dysphagia |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Enterocolitis |
5/661 (0.76%)
|
5 |
3/109 (2.75%)
|
3 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Esophageal pain |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Esophagitis |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Fecal incontinence |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Flatulence |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Gastritis |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
2/127 (1.57%)
|
8 |
0/27 (0.00%)
|
0 |
Gastroesophageal reflux disease |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
2/107 (1.87%)
|
2 |
3/129 (2.33%)
|
3 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Gastrointestinal disorders - Other, specify |
2/661 (0.30%)
|
2 |
3/109 (2.75%)
|
3 |
2/107 (1.87%)
|
2 |
2/129 (1.55%)
|
2 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Gastrointestinal pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Gingival pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hemorrhoids |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
2 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Ileus |
7/661 (1.06%)
|
7 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Lower gastrointestinal hemorrhage |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Malabsorption |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Mucositis oral |
37/661 (5.60%)
|
37 |
52/109 (47.71%)
|
63 |
5/107 (4.67%)
|
6 |
57/129 (44.19%)
|
89 |
42/127 (33.07%)
|
48 |
2/27 (7.41%)
|
2 |
Nausea |
13/661 (1.97%)
|
13 |
28/109 (25.69%)
|
40 |
34/107 (31.78%)
|
46 |
46/129 (35.66%)
|
57 |
33/127 (25.98%)
|
55 |
11/27 (40.74%)
|
14 |
Oral hemorrhage |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
4/129 (3.10%)
|
5 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Oral pain |
3/661 (0.45%)
|
3 |
5/109 (4.59%)
|
5 |
2/107 (1.87%)
|
2 |
9/129 (6.98%)
|
10 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Pancreatitis |
18/661 (2.72%)
|
18 |
4/109 (3.67%)
|
4 |
0/107 (0.00%)
|
0 |
3/129 (2.33%)
|
3 |
3/127 (2.36%)
|
3 |
0/27 (0.00%)
|
0 |
Periodontal disease |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Proctitis |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Rectal fistula |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Rectal hemorrhage |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Rectal mucositis |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Rectal pain |
1/661 (0.15%)
|
1 |
7/109 (6.42%)
|
8 |
1/107 (0.93%)
|
1 |
4/129 (3.10%)
|
4 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Rectal ulcer |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Small intestinal mucositis |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Stomach pain |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
2 |
3/129 (2.33%)
|
3 |
3/127 (2.36%)
|
3 |
0/27 (0.00%)
|
0 |
Toothache |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
2/129 (1.55%)
|
2 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Typhlitis |
19/661 (2.87%)
|
19 |
5/109 (4.59%)
|
5 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Vomiting |
6/661 (0.91%)
|
6 |
31/109 (28.44%)
|
43 |
23/107 (21.50%)
|
29 |
42/129 (32.56%)
|
52 |
25/127 (19.69%)
|
36 |
9/27 (33.33%)
|
11 |
General disorders |
|
|
|
|
|
|
Chills |
0/661 (0.00%)
|
0 |
7/109 (6.42%)
|
9 |
8/107 (7.48%)
|
10 |
12/129 (9.30%)
|
13 |
12/127 (9.45%)
|
12 |
0/27 (0.00%)
|
0 |
Edema face |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
7/107 (6.54%)
|
7 |
3/129 (2.33%)
|
3 |
3/127 (2.36%)
|
3 |
0/27 (0.00%)
|
0 |
Edema limbs |
1/661 (0.15%)
|
1 |
5/109 (4.59%)
|
6 |
3/107 (2.80%)
|
4 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Edema trunk |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Facial pain |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Fatigue |
2/661 (0.30%)
|
2 |
17/109 (15.60%)
|
19 |
15/107 (14.02%)
|
18 |
29/129 (22.48%)
|
39 |
25/127 (19.69%)
|
31 |
4/27 (14.81%)
|
4 |
Fever |
14/661 (2.12%)
|
14 |
39/109 (35.78%)
|
48 |
56/107 (52.34%)
|
76 |
52/129 (40.31%)
|
64 |
75/127 (59.06%)
|
121 |
17/27 (62.96%)
|
34 |
Flu like symptoms |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
3/129 (2.33%)
|
3 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Gait disturbance |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
2 |
1/107 (0.93%)
|
1 |
3/129 (2.33%)
|
3 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
General disorders and administration site conditions - Other, specify |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
2 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Hypothermia |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Infusion related reaction |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
3 |
1/107 (0.93%)
|
1 |
7/129 (5.43%)
|
14 |
3/127 (2.36%)
|
3 |
1/27 (3.70%)
|
1 |
Infusion site extravasation |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Injection site reaction |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Irritability |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
5 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
3/127 (2.36%)
|
3 |
0/27 (0.00%)
|
0 |
Localized edema |
1/661 (0.15%)
|
1 |
2/109 (1.83%)
|
2 |
2/107 (1.87%)
|
2 |
3/129 (2.33%)
|
3 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Malaise |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
3 |
2/107 (1.87%)
|
2 |
4/129 (3.10%)
|
4 |
3/127 (2.36%)
|
4 |
0/27 (0.00%)
|
0 |
Multi-organ failure |
1/661 (0.15%)
|
1 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Neck edema |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Non-cardiac chest pain |
2/661 (0.30%)
|
2 |
1/109 (0.92%)
|
1 |
2/107 (1.87%)
|
3 |
4/129 (3.10%)
|
4 |
6/127 (4.72%)
|
7 |
0/27 (0.00%)
|
0 |
Pain |
11/661 (1.66%)
|
13 |
11/109 (10.09%)
|
13 |
16/107 (14.95%)
|
21 |
18/129 (13.95%)
|
28 |
16/127 (12.60%)
|
22 |
4/27 (14.81%)
|
5 |
Hepatobiliary disorders |
|
|
|
|
|
|
Cholecystitis |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hepatic failure |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hepatobiliary disorders - Other, specify |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
4/129 (3.10%)
|
4 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
6 |
Portal hypertension |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Portal vein thrombosis |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Immune system disorders |
|
|
|
|
|
|
Allergic reaction |
2/661 (0.30%)
|
2 |
6/109 (5.50%)
|
6 |
1/107 (0.93%)
|
1 |
9/129 (6.98%)
|
11 |
5/127 (3.94%)
|
5 |
1/27 (3.70%)
|
1 |
Anaphylaxis |
5/661 (0.76%)
|
5 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
4/129 (3.10%)
|
4 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Autoimmune disorder |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cytokine release syndrome |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
19/107 (17.76%)
|
21 |
0/129 (0.00%)
|
0 |
14/127 (11.02%)
|
23 |
5/27 (18.52%)
|
5 |
Immune system disorders - Other, specify |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
4/107 (3.74%)
|
4 |
2/129 (1.55%)
|
3 |
6/127 (4.72%)
|
10 |
0/27 (0.00%)
|
0 |
Infections and infestations |
|
|
|
|
|
|
Abdominal infection |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Anorectal infection |
6/661 (0.91%)
|
6 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Appendicitis |
3/661 (0.45%)
|
3 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Appendicitis perforated |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Bladder infection |
2/661 (0.30%)
|
2 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Bone infection |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Bronchial infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
3 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Catheter related infection |
21/661 (3.18%)
|
26 |
8/109 (7.34%)
|
11 |
0/107 (0.00%)
|
0 |
8/129 (6.20%)
|
8 |
5/127 (3.94%)
|
7 |
0/27 (0.00%)
|
0 |
Cecal infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Conjunctivitis infective |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cranial nerve infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Device related infection |
2/661 (0.30%)
|
2 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Encephalitis infection |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Endocarditis infective |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Enterocolitis infectious |
6/661 (0.91%)
|
6 |
6/109 (5.50%)
|
6 |
0/107 (0.00%)
|
0 |
10/129 (7.75%)
|
14 |
7/127 (5.51%)
|
9 |
0/27 (0.00%)
|
0 |
Esophageal infection |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Eye infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
2 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Gum infection |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hepatic infection |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Infections and infestations - Other, specify |
115/661 (17.40%)
|
150 |
32/109 (29.36%)
|
48 |
11/107 (10.28%)
|
17 |
56/129 (43.41%)
|
97 |
30/127 (23.62%)
|
35 |
3/27 (11.11%)
|
3 |
Infective myositis |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Joint infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Kidney infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
3/129 (2.33%)
|
4 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Lip infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
3 |
2/129 (1.55%)
|
2 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Lung infection |
34/661 (5.14%)
|
34 |
10/109 (9.17%)
|
12 |
2/107 (1.87%)
|
2 |
19/129 (14.73%)
|
25 |
12/127 (9.45%)
|
26 |
2/27 (7.41%)
|
2 |
Lymph gland infection |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Meningitis |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Mucosal infection |
6/661 (0.91%)
|
6 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
2/129 (1.55%)
|
3 |
1/127 (0.79%)
|
2 |
1/27 (3.70%)
|
1 |
Nail infection |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Otitis externa |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Otitis media |
2/661 (0.30%)
|
3 |
3/109 (2.75%)
|
3 |
2/107 (1.87%)
|
3 |
5/129 (3.88%)
|
7 |
8/127 (6.30%)
|
11 |
1/27 (3.70%)
|
1 |
Papulopustular rash |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
3/129 (2.33%)
|
3 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Paronychia |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
2 |
1/129 (0.78%)
|
2 |
5/127 (3.94%)
|
5 |
0/27 (0.00%)
|
0 |
Penile infection |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Periorbital infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Pharyngitis |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Rash pustular |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Rhinitis infective |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Scrotal infection |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Sepsis |
39/661 (5.90%)
|
41 |
18/109 (16.51%)
|
19 |
0/107 (0.00%)
|
0 |
21/129 (16.28%)
|
24 |
10/127 (7.87%)
|
10 |
0/27 (0.00%)
|
0 |
Sinusitis |
9/661 (1.36%)
|
9 |
3/109 (2.75%)
|
3 |
2/107 (1.87%)
|
2 |
12/129 (9.30%)
|
12 |
3/127 (2.36%)
|
3 |
2/27 (7.41%)
|
2 |
Skin infection |
12/661 (1.82%)
|
12 |
9/109 (8.26%)
|
10 |
2/107 (1.87%)
|
2 |
13/129 (10.08%)
|
15 |
8/127 (6.30%)
|
10 |
2/27 (7.41%)
|
2 |
Small intestine infection |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
4 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Soft tissue infection |
3/661 (0.45%)
|
3 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
4/129 (3.10%)
|
6 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Splenic infection |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Tooth infection |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Upper respiratory infection |
6/661 (0.91%)
|
6 |
13/109 (11.93%)
|
19 |
5/107 (4.67%)
|
5 |
20/129 (15.50%)
|
29 |
18/127 (14.17%)
|
34 |
0/27 (0.00%)
|
0 |
Urinary tract infection |
6/661 (0.91%)
|
6 |
10/109 (9.17%)
|
11 |
1/107 (0.93%)
|
1 |
9/129 (6.98%)
|
17 |
8/127 (6.30%)
|
10 |
0/27 (0.00%)
|
0 |
Vulval infection |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Wound infection |
4/661 (0.61%)
|
4 |
2/109 (1.83%)
|
2 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Injury, poisoning and procedural complications |
|
|
|
|
|
|
Ankle fracture |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Bruising |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
3 |
1/107 (0.93%)
|
1 |
5/129 (3.88%)
|
8 |
3/127 (2.36%)
|
4 |
0/27 (0.00%)
|
0 |
Burn |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Dermatitis radiation |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Fall |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
2 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Fracture |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Injury, poisoning and procedural complications - Other, specify |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
4/129 (3.10%)
|
4 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Postoperative hemorrhage |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Stomal ulcer |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Vascular access complication |
2/661 (0.30%)
|
2 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
4/127 (3.15%)
|
5 |
0/27 (0.00%)
|
0 |
Wound complication |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Investigations |
|
|
|
|
|
|
Activated partial thromboplastin time prolonged |
6/661 (0.91%)
|
6 |
10/109 (9.17%)
|
11 |
6/107 (5.61%)
|
6 |
6/129 (4.65%)
|
6 |
3/127 (2.36%)
|
3 |
1/27 (3.70%)
|
1 |
Alanine aminotransferase increased |
90/661 (13.62%)
|
93 |
67/109 (61.47%)
|
110 |
76/107 (71.03%)
|
107 |
102/129 (79.07%)
|
363 |
92/127 (72.44%)
|
243 |
17/27 (62.96%)
|
23 |
Alkaline phosphatase increased |
2/661 (0.30%)
|
2 |
18/109 (16.51%)
|
25 |
21/107 (19.63%)
|
27 |
14/129 (10.85%)
|
19 |
15/127 (11.81%)
|
22 |
4/27 (14.81%)
|
7 |
Aspartate aminotransferase increased |
46/661 (6.96%)
|
46 |
57/109 (52.29%)
|
88 |
58/107 (54.21%)
|
78 |
83/129 (64.34%)
|
185 |
67/127 (52.76%)
|
115 |
15/27 (55.56%)
|
21 |
Blood bilirubin increased |
44/661 (6.66%)
|
46 |
41/109 (37.61%)
|
54 |
20/107 (18.69%)
|
22 |
61/129 (47.29%)
|
117 |
28/127 (22.05%)
|
59 |
3/27 (11.11%)
|
3 |
CD4 lymphocytes decreased |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
CPK increased |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cholesterol high |
1/661 (0.15%)
|
1 |
5/109 (4.59%)
|
7 |
3/107 (2.80%)
|
4 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Creatinine increased |
3/661 (0.45%)
|
3 |
5/109 (4.59%)
|
6 |
2/107 (1.87%)
|
2 |
13/129 (10.08%)
|
15 |
5/127 (3.94%)
|
5 |
2/27 (7.41%)
|
2 |
Ejection fraction decreased |
3/661 (0.45%)
|
3 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Electrocardiogram QT corrected interval prolonged |
1/661 (0.15%)
|
1 |
3/109 (2.75%)
|
3 |
3/107 (2.80%)
|
3 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Fibrinogen decreased |
11/661 (1.66%)
|
11 |
4/109 (3.67%)
|
4 |
4/107 (3.74%)
|
9 |
1/129 (0.78%)
|
1 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
GGT increased |
13/661 (1.97%)
|
13 |
13/109 (11.93%)
|
19 |
11/107 (10.28%)
|
13 |
14/129 (10.85%)
|
21 |
10/127 (7.87%)
|
14 |
1/27 (3.70%)
|
1 |
Hemoglobin increased |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
5/107 (4.67%)
|
5 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
INR increased |
2/661 (0.30%)
|
2 |
6/109 (5.50%)
|
8 |
6/107 (5.61%)
|
6 |
4/129 (3.10%)
|
4 |
1/127 (0.79%)
|
1 |
4/27 (14.81%)
|
4 |
Investigations - Other, specify |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
4 |
7/107 (6.54%)
|
15 |
4/129 (3.10%)
|
6 |
9/127 (7.09%)
|
24 |
2/27 (7.41%)
|
2 |
Lipase increased |
27/661 (4.08%)
|
27 |
5/109 (4.59%)
|
5 |
0/107 (0.00%)
|
0 |
5/129 (3.88%)
|
7 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Lymphocyte count decreased |
4/661 (0.61%)
|
4 |
37/109 (33.94%)
|
64 |
54/107 (50.47%)
|
86 |
65/129 (50.39%)
|
163 |
72/127 (56.69%)
|
181 |
11/27 (40.74%)
|
28 |
Lymphocyte count increased |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Neutrophil count decreased |
15/661 (2.27%)
|
15 |
62/109 (56.88%)
|
103 |
62/107 (57.94%)
|
103 |
87/129 (67.44%)
|
232 |
90/127 (70.87%)
|
218 |
19/27 (70.37%)
|
30 |
Platelet count decreased |
10/661 (1.51%)
|
10 |
71/109 (65.14%)
|
122 |
49/107 (45.79%)
|
68 |
81/129 (62.79%)
|
185 |
71/127 (55.91%)
|
125 |
21/27 (77.78%)
|
35 |
Serum amylase increased |
7/661 (1.06%)
|
7 |
6/109 (5.50%)
|
6 |
1/107 (0.93%)
|
1 |
3/129 (2.33%)
|
3 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Urine output decreased |
2/661 (0.30%)
|
2 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
3 |
0/27 (0.00%)
|
0 |
Weight gain |
1/661 (0.15%)
|
1 |
3/109 (2.75%)
|
3 |
5/107 (4.67%)
|
6 |
6/129 (4.65%)
|
11 |
9/127 (7.09%)
|
21 |
2/27 (7.41%)
|
2 |
Weight loss |
10/661 (1.51%)
|
10 |
8/109 (7.34%)
|
9 |
5/107 (4.67%)
|
6 |
12/129 (9.30%)
|
14 |
9/127 (7.09%)
|
9 |
2/27 (7.41%)
|
2 |
White blood cell decreased |
7/661 (1.06%)
|
7 |
64/109 (58.72%)
|
116 |
75/107 (70.09%)
|
128 |
81/129 (62.79%)
|
252 |
92/127 (72.44%)
|
244 |
17/27 (62.96%)
|
28 |
Metabolism and nutrition disorders |
|
|
|
|
|
|
Acidosis |
5/661 (0.76%)
|
5 |
4/109 (3.67%)
|
4 |
3/107 (2.80%)
|
3 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Alkalosis |
1/661 (0.15%)
|
1 |
2/109 (1.83%)
|
2 |
1/107 (0.93%)
|
1 |
3/129 (2.33%)
|
3 |
1/127 (0.79%)
|
2 |
1/27 (3.70%)
|
1 |
Anorexia |
41/661 (6.20%)
|
41 |
21/109 (19.27%)
|
26 |
14/107 (13.08%)
|
17 |
30/129 (23.26%)
|
41 |
17/127 (13.39%)
|
22 |
5/27 (18.52%)
|
5 |
Dehydration |
12/661 (1.82%)
|
12 |
8/109 (7.34%)
|
8 |
3/107 (2.80%)
|
3 |
11/129 (8.53%)
|
13 |
9/127 (7.09%)
|
9 |
0/27 (0.00%)
|
0 |
Glucose intolerance |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Hypercalcemia |
0/661 (0.00%)
|
0 |
4/109 (3.67%)
|
5 |
8/107 (7.48%)
|
10 |
4/129 (3.10%)
|
4 |
5/127 (3.94%)
|
6 |
4/27 (14.81%)
|
9 |
Hyperglycemia |
109/661 (16.49%)
|
110 |
37/109 (33.94%)
|
54 |
47/107 (43.93%)
|
71 |
51/129 (39.53%)
|
74 |
53/127 (41.73%)
|
118 |
15/27 (55.56%)
|
19 |
Hyperkalemia |
11/661 (1.66%)
|
11 |
12/109 (11.01%)
|
14 |
10/107 (9.35%)
|
11 |
15/129 (11.63%)
|
16 |
10/127 (7.87%)
|
10 |
1/27 (3.70%)
|
1 |
Hypermagnesemia |
2/661 (0.30%)
|
2 |
5/109 (4.59%)
|
5 |
2/107 (1.87%)
|
2 |
10/129 (7.75%)
|
11 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Hypernatremia |
3/661 (0.45%)
|
3 |
19/109 (17.43%)
|
22 |
9/107 (8.41%)
|
10 |
17/129 (13.18%)
|
22 |
7/127 (5.51%)
|
12 |
2/27 (7.41%)
|
2 |
Hypertriglyceridemia |
19/661 (2.87%)
|
19 |
12/109 (11.01%)
|
13 |
3/107 (2.80%)
|
3 |
7/129 (5.43%)
|
7 |
8/127 (6.30%)
|
12 |
1/27 (3.70%)
|
1 |
Hyperuricemia |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
3/107 (2.80%)
|
5 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hypoalbuminemia |
41/661 (6.20%)
|
42 |
52/109 (47.71%)
|
79 |
55/107 (51.40%)
|
70 |
58/129 (44.96%)
|
82 |
49/127 (38.58%)
|
83 |
14/27 (51.85%)
|
21 |
Hypocalcemia |
32/661 (4.84%)
|
33 |
47/109 (43.12%)
|
68 |
33/107 (30.84%)
|
42 |
48/129 (37.21%)
|
64 |
44/127 (34.65%)
|
66 |
11/27 (40.74%)
|
11 |
Hypoglycemia |
2/661 (0.30%)
|
2 |
19/109 (17.43%)
|
22 |
9/107 (8.41%)
|
9 |
12/129 (9.30%)
|
14 |
3/127 (2.36%)
|
5 |
5/27 (18.52%)
|
5 |
Hypokalemia |
76/661 (11.50%)
|
76 |
54/109 (49.54%)
|
79 |
39/107 (36.45%)
|
50 |
61/129 (47.29%)
|
112 |
55/127 (43.31%)
|
93 |
13/27 (48.15%)
|
17 |
Hypomagnesemia |
1/661 (0.15%)
|
1 |
29/109 (26.61%)
|
37 |
18/107 (16.82%)
|
22 |
31/129 (24.03%)
|
36 |
15/127 (11.81%)
|
20 |
11/27 (40.74%)
|
11 |
Hyponatremia |
57/661 (8.62%)
|
59 |
31/109 (28.44%)
|
38 |
29/107 (27.10%)
|
39 |
35/129 (27.13%)
|
44 |
23/127 (18.11%)
|
34 |
8/27 (29.63%)
|
9 |
Hypophosphatemia |
50/661 (7.56%)
|
50 |
24/109 (22.02%)
|
31 |
24/107 (22.43%)
|
28 |
32/129 (24.81%)
|
35 |
15/127 (11.81%)
|
21 |
9/27 (33.33%)
|
13 |
Metabolism and nutrition disorders - Other, specify |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
2 |
2/107 (1.87%)
|
2 |
3/129 (2.33%)
|
4 |
2/127 (1.57%)
|
3 |
1/27 (3.70%)
|
1 |
Obesity |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
4 |
0/27 (0.00%)
|
0 |
Tumor lysis syndrome |
8/661 (1.21%)
|
8 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Musculoskeletal and connective tissue disorders |
|
|
|
|
|
|
Arthralgia |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
4 |
6/107 (5.61%)
|
7 |
3/129 (2.33%)
|
4 |
4/127 (3.15%)
|
5 |
1/27 (3.70%)
|
1 |
Avascular necrosis |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
3 |
3/129 (2.33%)
|
4 |
3/127 (2.36%)
|
4 |
0/27 (0.00%)
|
0 |
Back pain |
7/661 (1.06%)
|
7 |
11/109 (10.09%)
|
12 |
15/107 (14.02%)
|
19 |
16/129 (12.40%)
|
21 |
25/127 (19.69%)
|
28 |
4/27 (14.81%)
|
4 |
Bone pain |
0/661 (0.00%)
|
0 |
4/109 (3.67%)
|
6 |
3/107 (2.80%)
|
4 |
6/129 (4.65%)
|
6 |
4/127 (3.15%)
|
4 |
4/27 (14.81%)
|
4 |
Buttock pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Chest wall pain |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Flank pain |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Generalized muscle weakness |
1/661 (0.15%)
|
1 |
4/109 (3.67%)
|
4 |
3/107 (2.80%)
|
3 |
6/129 (4.65%)
|
6 |
5/127 (3.94%)
|
5 |
1/27 (3.70%)
|
1 |
Joint effusion |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Joint range of motion decreased |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Muscle weakness left-sided |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Muscle weakness lower limb |
1/661 (0.15%)
|
1 |
2/109 (1.83%)
|
3 |
3/107 (2.80%)
|
3 |
0/129 (0.00%)
|
0 |
4/127 (3.15%)
|
5 |
0/27 (0.00%)
|
0 |
Muscle weakness trunk |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Musculoskeletal and connective tissue disorder - Other, specify |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
2/127 (1.57%)
|
2 |
2/27 (7.41%)
|
2 |
Myalgia |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
4 |
8/107 (7.48%)
|
9 |
9/129 (6.98%)
|
10 |
8/127 (6.30%)
|
11 |
0/27 (0.00%)
|
0 |
Neck pain |
1/661 (0.15%)
|
1 |
3/109 (2.75%)
|
4 |
3/107 (2.80%)
|
3 |
4/129 (3.10%)
|
4 |
7/127 (5.51%)
|
7 |
0/27 (0.00%)
|
0 |
Osteoporosis |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Pain in extremity |
7/661 (1.06%)
|
7 |
17/109 (15.60%)
|
22 |
15/107 (14.02%)
|
21 |
15/129 (11.63%)
|
18 |
26/127 (20.47%)
|
37 |
8/27 (29.63%)
|
10 |
Trismus |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
|
|
|
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Nervous system disorders |
|
|
|
|
|
|
Akathisia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Amnesia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Ataxia |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Cerebrospinal fluid leakage |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Concentration impairment |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
2/127 (1.57%)
|
3 |
0/27 (0.00%)
|
0 |
Depressed level of consciousness |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Dizziness |
0/661 (0.00%)
|
0 |
7/109 (6.42%)
|
8 |
8/107 (7.48%)
|
8 |
5/129 (3.88%)
|
6 |
11/127 (8.66%)
|
11 |
0/27 (0.00%)
|
0 |
Dysarthria |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Dysgeusia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Dysphasia |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Encephalopathy |
4/661 (0.61%)
|
4 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
4/129 (3.10%)
|
4 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Extrapyramidal disorder |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Facial muscle weakness |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Facial nerve disorder |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Headache |
11/661 (1.66%)
|
12 |
20/109 (18.35%)
|
26 |
36/107 (33.64%)
|
54 |
36/129 (27.91%)
|
53 |
56/127 (44.09%)
|
90 |
11/27 (40.74%)
|
14 |
Hydrocephalus |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hypersomnia |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Intracranial hemorrhage |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Lethargy |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Leukoencephalopathy |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Memory impairment |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
3/127 (2.36%)
|
3 |
0/27 (0.00%)
|
0 |
Movements involuntary |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
2 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Nervous system disorders - Other, specify |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
4 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
3 |
Neuralgia |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Oculomotor nerve disorder |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Paresthesia |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
6/107 (5.61%)
|
6 |
1/129 (0.78%)
|
1 |
6/127 (4.72%)
|
6 |
0/27 (0.00%)
|
0 |
Peripheral motor neuropathy |
5/661 (0.76%)
|
5 |
9/109 (8.26%)
|
11 |
4/107 (3.74%)
|
4 |
8/129 (6.20%)
|
11 |
4/127 (3.15%)
|
6 |
1/27 (3.70%)
|
1 |
Peripheral sensory neuropathy |
7/661 (1.06%)
|
7 |
9/109 (8.26%)
|
10 |
8/107 (7.48%)
|
9 |
3/129 (2.33%)
|
4 |
7/127 (5.51%)
|
8 |
4/27 (14.81%)
|
4 |
Presyncope |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Reversible posterior leukoencephalopathy syndrome |
1/661 (0.15%)
|
1 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Seizure |
3/661 (0.45%)
|
3 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
3/129 (2.33%)
|
3 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Somnolence |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
2/127 (1.57%)
|
2 |
2/27 (7.41%)
|
2 |
Syncope |
8/661 (1.21%)
|
8 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Tremor |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
9/107 (8.41%)
|
11 |
4/129 (3.10%)
|
4 |
22/127 (17.32%)
|
32 |
1/27 (3.70%)
|
1 |
Vasovagal reaction |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Psychiatric disorders |
|
|
|
|
|
|
Agitation |
2/661 (0.30%)
|
2 |
2/109 (1.83%)
|
2 |
6/107 (5.61%)
|
7 |
2/129 (1.55%)
|
5 |
6/127 (4.72%)
|
8 |
2/27 (7.41%)
|
2 |
Anxiety |
2/661 (0.30%)
|
2 |
4/109 (3.67%)
|
5 |
11/107 (10.28%)
|
13 |
11/129 (8.53%)
|
12 |
14/127 (11.02%)
|
21 |
4/27 (14.81%)
|
4 |
Confusion |
2/661 (0.30%)
|
2 |
3/109 (2.75%)
|
3 |
7/107 (6.54%)
|
7 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
2/27 (7.41%)
|
2 |
Delirium |
4/661 (0.61%)
|
4 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Delusions |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Depression |
0/661 (0.00%)
|
0 |
4/109 (3.67%)
|
5 |
7/107 (6.54%)
|
10 |
7/129 (5.43%)
|
12 |
5/127 (3.94%)
|
9 |
1/27 (3.70%)
|
1 |
Euphoria |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Hallucinations |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
3 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Insomnia |
1/661 (0.15%)
|
1 |
4/109 (3.67%)
|
5 |
3/107 (2.80%)
|
3 |
8/129 (6.20%)
|
12 |
7/127 (5.51%)
|
8 |
0/27 (0.00%)
|
0 |
Mania |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Personality change |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
3/127 (2.36%)
|
3 |
0/27 (0.00%)
|
0 |
Psychiatric disorders - Other, specify |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Psychosis |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Restlessness |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Suicidal ideation |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Suicide attempt |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Renal and urinary disorders |
|
|
|
|
|
|
Acute kidney injury |
3/661 (0.45%)
|
3 |
5/109 (4.59%)
|
6 |
1/107 (0.93%)
|
1 |
2/129 (1.55%)
|
2 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Bladder spasm |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cystitis noninfective |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Hematuria |
1/661 (0.15%)
|
1 |
7/109 (6.42%)
|
7 |
1/107 (0.93%)
|
1 |
4/129 (3.10%)
|
4 |
4/127 (3.15%)
|
4 |
2/27 (7.41%)
|
2 |
Hemoglobinuria |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Proteinuria |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Renal and urinary disorders - Other, specify |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
3 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
2 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Urinary frequency |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Urinary incontinence |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
2/107 (1.87%)
|
2 |
2/129 (1.55%)
|
2 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Urinary retention |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Urinary tract pain |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
2/107 (1.87%)
|
3 |
2/129 (1.55%)
|
2 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Urinary urgency |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Urine discoloration |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Reproductive system and breast disorders |
|
|
|
|
|
|
Dysmenorrhea |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Genital edema |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Menorrhagia |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Penile pain |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Perineal pain |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
3 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Reproductive system and breast disorders - Other, specify |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Scrotal pain |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Testicular pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Vaginal inflammation |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
2 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Vaginal pain |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Respiratory, thoracic and mediastinal disorders |
|
|
|
|
|
|
Adult respiratory distress syndrome |
3/661 (0.45%)
|
3 |
2/109 (1.83%)
|
2 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Allergic rhinitis |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
3/107 (2.80%)
|
6 |
5/129 (3.88%)
|
7 |
6/127 (4.72%)
|
10 |
0/27 (0.00%)
|
0 |
Aspiration |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Atelectasis |
1/661 (0.15%)
|
1 |
2/109 (1.83%)
|
2 |
2/107 (1.87%)
|
3 |
4/129 (3.10%)
|
4 |
1/127 (0.79%)
|
2 |
0/27 (0.00%)
|
0 |
Bronchopulmonary hemorrhage |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Cough |
0/661 (0.00%)
|
0 |
18/109 (16.51%)
|
24 |
12/107 (11.21%)
|
16 |
27/129 (20.93%)
|
32 |
30/127 (23.62%)
|
37 |
4/27 (14.81%)
|
4 |
Dyspnea |
3/661 (0.45%)
|
3 |
8/109 (7.34%)
|
8 |
3/107 (2.80%)
|
3 |
9/129 (6.98%)
|
10 |
6/127 (4.72%)
|
6 |
1/27 (3.70%)
|
1 |
Epistaxis |
8/661 (1.21%)
|
8 |
7/109 (6.42%)
|
8 |
1/107 (0.93%)
|
1 |
18/129 (13.95%)
|
19 |
5/127 (3.94%)
|
5 |
2/27 (7.41%)
|
3 |
Hiccups |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hoarseness |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Hypoxia |
12/661 (1.82%)
|
12 |
12/109 (11.01%)
|
13 |
1/107 (0.93%)
|
1 |
21/129 (16.28%)
|
21 |
9/127 (7.09%)
|
9 |
2/27 (7.41%)
|
3 |
Laryngeal edema |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Laryngeal inflammation |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Laryngeal mucositis |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Laryngospasm |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Nasal congestion |
0/661 (0.00%)
|
0 |
6/109 (5.50%)
|
7 |
3/107 (2.80%)
|
5 |
14/129 (10.85%)
|
15 |
16/127 (12.60%)
|
19 |
2/27 (7.41%)
|
2 |
Pharyngeal mucositis |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Pleural effusion |
4/661 (0.61%)
|
4 |
1/109 (0.92%)
|
2 |
1/107 (0.93%)
|
1 |
6/129 (4.65%)
|
7 |
2/127 (1.57%)
|
2 |
1/27 (3.70%)
|
1 |
Pneumonitis |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Pneumothorax |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Postnasal drip |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Productive cough |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
2/107 (1.87%)
|
3 |
3/129 (2.33%)
|
3 |
3/127 (2.36%)
|
3 |
0/27 (0.00%)
|
0 |
Pulmonary edema |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
4/129 (3.10%)
|
4 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Respiratory failure |
4/661 (0.61%)
|
4 |
1/109 (0.92%)
|
2 |
1/107 (0.93%)
|
1 |
3/129 (2.33%)
|
3 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Respiratory, thoracic and mediastinal disorders - Other, specify |
0/661 (0.00%)
|
0 |
3/109 (2.75%)
|
6 |
3/107 (2.80%)
|
10 |
2/129 (1.55%)
|
3 |
5/127 (3.94%)
|
8 |
2/27 (7.41%)
|
4 |
Sleep apnea |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Sore throat |
4/661 (0.61%)
|
4 |
4/109 (3.67%)
|
5 |
4/107 (3.74%)
|
5 |
10/129 (7.75%)
|
11 |
12/127 (9.45%)
|
13 |
0/27 (0.00%)
|
0 |
Stridor |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Tracheal mucositis |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Voice alteration |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Wheezing |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Skin and subcutaneous tissue disorders |
|
|
|
|
|
|
Alopecia |
0/661 (0.00%)
|
0 |
5/109 (4.59%)
|
7 |
9/107 (8.41%)
|
12 |
6/129 (4.65%)
|
7 |
13/127 (10.24%)
|
19 |
2/27 (7.41%)
|
2 |
Bullous dermatitis |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Dry skin |
0/661 (0.00%)
|
0 |
2/109 (1.83%)
|
2 |
2/107 (1.87%)
|
2 |
4/129 (3.10%)
|
4 |
6/127 (4.72%)
|
7 |
0/27 (0.00%)
|
0 |
Erythema multiforme |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Hyperhidrosis |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
2/107 (1.87%)
|
2 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Nail discoloration |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Nail loss |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Pain of skin |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
3/127 (2.36%)
|
3 |
0/27 (0.00%)
|
0 |
Palmar-plantar erythrodysesthesia syndrome |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
2 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Periorbital edema |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Photosensitivity |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Pruritus |
0/661 (0.00%)
|
0 |
7/109 (6.42%)
|
7 |
7/107 (6.54%)
|
9 |
5/129 (3.88%)
|
5 |
15/127 (11.81%)
|
18 |
2/27 (7.41%)
|
3 |
Purpura |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Rash acneiform |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
1/129 (0.78%)
|
1 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Rash maculo-papular |
8/661 (1.21%)
|
8 |
11/109 (10.09%)
|
12 |
20/107 (18.69%)
|
26 |
16/129 (12.40%)
|
17 |
22/127 (17.32%)
|
26 |
3/27 (11.11%)
|
4 |
Skin and subcutaneous tissue disorders - Other, specify |
1/661 (0.15%)
|
1 |
7/109 (6.42%)
|
7 |
10/107 (9.35%)
|
13 |
11/129 (8.53%)
|
11 |
9/127 (7.09%)
|
11 |
3/27 (11.11%)
|
3 |
Skin atrophy |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Skin hyperpigmentation |
0/661 (0.00%)
|
0 |
4/109 (3.67%)
|
4 |
0/107 (0.00%)
|
0 |
1/129 (0.78%)
|
1 |
4/127 (3.15%)
|
4 |
0/27 (0.00%)
|
0 |
Skin hypopigmentation |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Skin induration |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Skin ulceration |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
1/107 (0.93%)
|
1 |
2/129 (1.55%)
|
2 |
2/127 (1.57%)
|
4 |
1/27 (3.70%)
|
1 |
Urticaria |
0/661 (0.00%)
|
0 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
2/129 (1.55%)
|
2 |
2/127 (1.57%)
|
2 |
0/27 (0.00%)
|
0 |
Surgical and medical procedures |
|
|
|
|
|
|
Surgical and medical procedures - Other, specify |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
2/129 (1.55%)
|
6 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Vascular disorders |
|
|
|
|
|
|
Capillary leak syndrome |
1/661 (0.15%)
|
1 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
2/129 (1.55%)
|
2 |
0/127 (0.00%)
|
0 |
1/27 (3.70%)
|
1 |
Flushing |
0/661 (0.00%)
|
0 |
4/109 (3.67%)
|
4 |
2/107 (1.87%)
|
2 |
2/129 (1.55%)
|
2 |
14/127 (11.02%)
|
17 |
2/27 (7.41%)
|
2 |
Hematoma |
1/661 (0.15%)
|
1 |
1/109 (0.92%)
|
1 |
0/107 (0.00%)
|
0 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
1/27 (3.70%)
|
1 |
Hot flashes |
0/661 (0.00%)
|
0 |
0/109 (0.00%)
|
0 |
1/107 (0.93%)
|
1 |
1/129 (0.78%)
|
1 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Hypertension |
22/661 (3.33%)
|
23 |
24/109 (22.02%)
|
33 |
18/107 (16.82%)
|
26 |
27/129 (20.93%)
|
34 |
15/127 (11.81%)
|
23 |
10/27 (37.04%)
|
12 |
Hypotension |
30/661 (4.54%)
|
30 |
16/109 (14.68%)
|
17 |
18/107 (16.82%)
|
25 |
21/129 (16.28%)
|
32 |
33/127 (25.98%)
|
49 |
4/27 (14.81%)
|
4 |
Thromboembolic event |
2/661 (0.30%)
|
2 |
0/109 (0.00%)
|
0 |
2/107 (1.87%)
|
2 |
5/129 (3.88%)
|
6 |
0/127 (0.00%)
|
0 |
0/27 (0.00%)
|
0 |
Vascular disorders - Other, specify |
1/661 (0.15%)
|
1 |
2/109 (1.83%)
|
2 |
1/107 (0.93%)
|
1 |
0/129 (0.00%)
|
0 |
1/127 (0.79%)
|
1 |
0/27 (0.00%)
|
0 |
Term from vocabulary, CTCv4
Indicates events were collected by systematic assessment
|